ARRAYit Corporation has reported that researchers at the National Institutes of Health (NIH), National Cancer Institute (NCI) and Northeastern University used the ARRAYit Microarray Platform to discover biomarkers important in the treatment of prostate cancer.

Pioneering authors Dr Christopher T Campbell, Dr James L Gulley, Dr Oyindasola Oyelaran, Dr James W Hodge, Dr Jeffrey Schlom, and Dr Jeffrey C Gildersleeve published a paper entitled "Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF" in the 2013 edition of Clinical Cancer Research.

The NCI scientists used ARRAYit's patented and proprietary SMP2 and SMP3 microarray printing technology to manufacture glycan microarrays containing miniaturized collections of carbohydrates that selectively react with IgG and IgM antibodies in serum derived from prostate cancer patients. This important retrospective study included 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials for advanced prostate cancer. The NCI microarrays manufactured using ARYC technology consistently stratified the patients into groups with different survival rates, suggesting that the test can be used to empower personalized medicine, which bases treatment options on the characteristics of individual patients.

The authors emphasize that, "By targeting treatment to likely responders, a predictive method can significantly improve clinical efficacy while simultaneously reducing health care costs."  ARRAYit technology offers the highest testing specificity and sensitivity on the market, which is increasingly allowing doctors to stratify their patients into responders, non-responders and adverse responders, a capability that is empowering safer and more efficacious treatment with life saving medicines.

ARRAYit Corporation is a leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.